Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma

Cancer Research

Volumn 62, Issue 24, 2002, Pages 7350-7356

  Ang, K Kian ^a   Berkey, Brian A ^a   Tu, Xiaoyu ^a   Zhang, Hua Zhong ^a   Katz, Ruth ^a   Hammond, Elizabeth H ^b   Fu, Karen K ^c   Milas, Luka ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAMINOBENZIDINE; EPIDERMAL GROWTH FACTOR RECEPTOR; HEMATOXYLIN; MONOCLONAL ANTIBODY;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HEAD AND NECK CARCINOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SIGNAL TRANSDUCTION;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III; DISEASE-FREE SURVIVAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASM STAGING; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037115674     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Ang, K. Altered fractionation in head and neck cancer. Semin. Radiat. Oncol., 8: 230-236, 1998.
2. Pignon, J. P., Bourhis, J., Domenge, C., and Designe, L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: Three meta-analyses of updated individual data. Lancet, 355: 949-955, 2000.
3. El-Sayed, S., and Nelson, N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomised trials. J. Clin. Oncol., 14: 838-847, 1996.
4. Smith, B. D., and Haffty, B. G. Molecular markers as prognostic factors for local recurrence and radioresistance in head and neck squamous cell carcinoma. Radiat. Oncol. Investig., 7: 125-144, 1999.
5. Salesiotis, A. N., and Cullen, K. J. Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: Evolution of a model beyond TNM staging. Curr. Opin. Oncol., 12: 229-239, 2000.
6. Quon, H., Liu, F. F., and Cummings, B. J. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck, 23: 147-159, 2001.
7. Fu, K. K., Pajak, T. F., Trotti, A., Jones, C. U., Spencer, S. A., Phillips, T. L., Garden, A. S., Ridge, J. A., Cooper, J. S., and Ang, K. K. A Radiation Therapy Oncology Group (RTOG) Phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: First report of RTOG 9003. Int. J. Radiat. Oncol. Biol. Phys., 48: 7-16, 2000.
8. Cooper, J., Famum, N., Asbell, S., Rotman, M., Marcial, V., Fu, K., McKenna, W., and Emani, B. Recursive partitioning analysis of 2,105 patients treated in RTOG studies of head and neck cancer. Cancer (Phila.), 77: 1905-1911, 1996.
9. Pearson, K. On the criterion that a given system of deviations from the probable in the case of correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. Philosophical Magazine, 53: 157-175, 1900.
10. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
11. Mantel, N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep., 5: 163-170, 1966.
12. Kalbfleish, J. and Prentice, R. The Statistical Analysis of Failure Time Data. New York: John Wiley and Sons, 1980.
13. Gray, R. J. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann. Stat., 16: 1141-1154, 1988.
14. Cox, D. R. Regression models and life tables. J. R. Stat. Soc., 34: 187-229, 1972.
15. Davis, R. L., Grosse, V. A., Kucherlapati, R., and Bothwell, M. Genetic analysis of epidermal growth factor action: Assignment of human epidermal growth factor receptor gene to chromosome 7. Proc. Natl. Acad. Sci., 77: 4188-4192, 1980.
16. Schlessinger, J., and Ullrich, A. Growth factor signaling by receptor tyrosine kinases. Neuron, 9: 383-391, 1992.
17. Zanke, B. Growth factors and intracellular signaling. In: I. F. Tannock and R. P. Hill (eds.), The Basic Science of Oncology, pp 106-133. New York: McGraw-Hill, 1998.
18. 2/M-phase arrest. Radiat. Res., 153: 371-383, 2000.
19. Huang, S. M., and Harari, P. M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin. Cancer Res., 6: 2166-2174, 2000.
20. Grandis, J., and Tweardy, D. Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res., 53: 3579-3584, 1993.
21. Grandis, J. R., Melhem, M. F., Barnes, E. L., and Tweardy, D. J. Quantitative immunohistochemical analysis of transformign growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer (Phila.), 78: 1284-1292, 1996.
22. Irish, J. C., and Bernstein, A. Oncogenes in head and neck cancer. Laryngoscope, 103: 42-52, 1993.
23. Miyaguchi, M., Olofosson, J., and Hellquist, H. B. Expression of epidermal growth factor receptor in glottic carcinoma and its relation to recurrence after radiotherapy. Clin. Otolaryngol., 16: 466-469, 1991.
24. Wen, Q. H., Miwa, T., Yoshizaki, T., Nagayama, I., Furukawa, M., and Nishijima, H. Prognostic value of EGFR and TGF-α in early laryngeal cancer treated with radiotherapy. Laryngoscope, 106: 884-888, 1996.
25. Maurizi, M., Almadori, G., Ferrandina, G., Distefano, M., Romanini, M., Cadoni, G., Benedetti-Panici, G., Paludetti, G., Scambia, G., and Mancuso, S. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br. J. Cancer, 74: 1253-1257, 1996.
26. Grandis, J., Melhem, M., Gooding, W., Day, R., Holst, V., Wagener, M., Drenning, S., and Tweardy, D. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J. Natl. Cancer Inst., 90: 824-832, 1998.
27. Sheridan, M. T., O'Dwyer, T., Seymour, C. B., and Mothersill, C. E. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radial. Oncol. Investig., 5: 180-186, 1997.
28. Balaban, N., Moni, J., Shannon, M., Dang, L., Murphy, E., and Goldkorn, T. The effect of ionizing radiation on signal transduction: Antibodies to EGF receptor sensitize A431 cells to radiation. Biochim. Biophys. Acta, 1314: 147-156, 1996.
29. Akimoto, T., Hunter, N. R., Buchmiller, L., Mason, K., Ang, K. K., and Milas, L. Inverse relationship between epidermal growth factor receptor expression and radio-curability of murine carcinomas. Clin. Cancer Res., 5: 437-443, 1999.
30. Goldstein. N. I., Prewett, M., Zuklys, K., Rockwell, P., and Mendelsohn, J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin. Cancer Res., 1: 1311-1318, 1995.
31. Hoffmann. T., Hafner, D., Ballo, H., Haas, I., and Bier, H. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res., 17: 4419-4425, 1997.
32. Grandis, J. R., Chakraborty, A., Melhem, M. F., Zeng, K., and Tweardy, D. J. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene, 15: 409-416, 1997.
33. Milas, L., Mason, K., Hunter, N., Petersen, S., Yamakawa, M., Ang, K. K., Mendelsohn, J., and Fan, Z. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin. Cancer Res., 6: 701-708, 2000.
34. Nasu, S., Ang, K. K., Fan, Z., and Milas, L. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int. J. Radiat. Oncol. Biol. Phys., 51: 474-477, 2001.
35. Shin, D. M., Donato, N. J., Perez-Soler, R., Shin, H. J. C., Wu, J. Y., Zhang, P., Lawhom, K., Khuri, F. R., Glisson, B. S., Myers, J., Clayman, G., Pfister, D., Falcey, J., Waksal, H., Mendelsohn, J., and Hong, W. K. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res., 7: 1204-1213, 2001.
36. Fry, D. W. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy: Progression from reversible to irreversible inhibitors. Pharmacol. Ther., 82: 207-218, 1999.
37. Noonberg, S. B., and Benz, C. C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs, 59: 753-767, 2000.
38. He, Y., Zeng, Q., Drenning, S. D., Melhem. M. F., Tweardy, D. J., Huang, L., and Grandis, J. R. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J. Natl. Cancer Inst., 90: 1080-1087, 1998.
39. Contessa, J. N., Reardon. D. B., Todd. D., Dent, P., Mikkelsen. R. B., Valerie, K., Bowers, G. D., and Schmidt-Ullrich, R. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin. Cancer Res., 5: 405-411, 1999.